<DOC>
	<DOCNO>NCT01936337</DOCNO>
	<brief_summary>In study , safety , tolerability efficacy DLX105 administer topically onto psoriatic lesion mild-to-moderate psoriasis patient investigate .</brief_summary>
	<brief_title>Topical Double-blind , Randomized , Placebo-controlled Study Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Signed date informed consent prior initiation study procedure . 2 . Male female Caucasian age 1875 year . 3 . Male female patient stable chronic mildtomoderate plaquetype psoriasis ( PASI ≤15 ) . 4 . Male female Caucasian patient stable chronic mildtomoderate plaquetype psoriasis ( PASI ≤15 ) age 1875 year must least two psoriasis lesion &gt; 9 cm2 ( locate arm and/or trunk , exclude elbow leg ) , stable least 3 month , local PASI score ≥8 . 5 . Affected body surface area ( BSA ) ≤10 % . 6 . Negative pregnancy test female childbearing potential ( premenopausal , &lt; 2 year postmenopausal , surgically sterile ) . 7 . Willing able participate trial outpatient comply trial requirement . 1 . Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic guttate psoriasis , palmar , plantar nail disease ) screening . 2 . Druginduced psoriasis ( i.e. , new onset current exacerbation betablockers , calcium channel inhibitor lithium ) prior randomization 3 . Ongoing use prohibit psoriasis treatment ( duration washout , i.e . discontinuation prior randomization ) : 1 . Biological agent , e.g . adalimumab , etanercept , infliximab , ustekinumab , alefacept ( 12 week ) 2 . Systemic therapy psoriasis psoriatic arthritis ( ) e.g . methotrexate , cyclosporin , fumaric acid ( derivative ) , systemic steroid ( 4 week ) 3 . Photochemotherapy e.g. , ultraviolet A psoralen ( PUVA ) ( 4 week ) 4 . Phototherapy e.g. , ultraviolet A ( UVA ) ultraviolet B ( UVB ) ( 2 week ) 5 . Topical therapy treatment Ps corticosteroid , vitamin D analogue retinoids within 14 day prior baseline 6 . Other investigational psoriasis drug ( 4 week 5 halflives , whichever long ) 4 . Intake investigational drug participation Clinical Trial within 4 week 5 halflives , ( whichever longer ) prior baseline . 5 . History evidence active tuberculosis . All patient test tuberculosis status use blood test ( QuantiFERON TBGold ) unless test perform within 4 month prior randomization negative . Patients evidence latent tuberculosis may enter trial sufficient treatment initiate accord local regulation . 6 . Active systemic infection ( common cold ) two week randomization 7 . Positive test hepatitis B C screen 8 . Positive test HIV screen 9 . History symptoms malignancy organ system ( history basal cell carcinoma / three squamous cell carcinoma skin , successful treatment perform , sign recurrence ; actinic keratosis , present screening , treat accord standard therapy randomization ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 10 . History severe hypersensitivity human humanize biological agent 11 . Any severe , progressive uncontrolled medical condition baseline judgment investigator prevents patient participate study . 12 . Any clinically significant abnormal laboratory test screen 13 . Active liver disease alanine aminotransferase ( ALT ) / aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal screen 14 . History moderate severe congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) 15 . Inability unwillingness undergo repeat venipuncture ( e.g. , due poor tolerability lack access vein ) 16 . History evidence drug alcohol abuse within 6 month prior first study drug administration 17 . Patients live vaccination within 6 week prior first study drug administration , require live vaccination course trial 18 . History hypersensitivity excipients study drug excipients similar chemical class 19 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human chorionic gonadotropin ( HCG ) laboratory test ( &gt; 5 mIU/mL ) 20 . Women childbearing potential , defined woman physiologically capable become pregnant . UNLESS woman whose partner sterilize vasectomy 1 . Using highly effective method birth control ( i.e . one result less 1 % per year failure rate use consistently correctly , implant , injectables , combine oral contraceptive , condom ( partner ) , intrauterine device ( IUDs ) ) . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal consider acceptable form birth control within study 2 . Reliable contraception maintain throughout study 2 week last study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>